Importantly, treatment of RAF1-proficient or -deficient CRC cell lines with the STAT3 inhibitor napabucasin (BBI608) [46] showed that STAT3 inhibition decreased proliferation to levels similar to RAF1 ablation in DLD1 and KM12, while it was more efficient than loss of RAF1 in SW1116 and less efficient in Caco2 cell lines (Supplementary Fig. S7A). The gene discussed is STAT3; the disease is colorectal carcinoma.